Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Right Tools, Right Time, Right Place
NCT07169409Phase 1Recruiting
- Sponsor
- Boulder Care
- Start
- Jun 2025
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buprenorphine in opioid use disorder (OUD), sponsored by Boulder Care. Primary endpoint: Intervention Acceptability, Appropriateness, Feasibility at 48 weeks. Started Jun 2025; status: recruiting.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07169409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169409.